Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Smolen

Showing results (1001-1010 of 1,467) with videos related to

Pageof 147
Sort By:
Arthritis and Rheumatism|July 13, 2004
Endothelial precursor cells in the synovial tissue of patients with rheumatoid arthritis and osteoarthritisBeate Rüger, Alexander Giurea, Axel H Wanivenhaus, et al.
Nature Reviews. Rheumatology|November 11, 2016
Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendationsLaure Gossec, Laura C Coates, Maarten de Wit, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2020
Structural Insights into Inhibition of the Acinetobacter-Derived Cephalosporinase ADC-7 by Ceftazidime and Its Boronic Acid Transition State AnalogBrandy N Curtis, Kali A Smolen, Sara J Barlow, et al.
Annals of the Rheumatic Diseases|October 28, 2021
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated databasePeter C Taylor, Tsutomu Takeuchi, Gerd R Burmester, et al.
RMD Open|August 21, 2023
Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysisEric Morand, Josef S Smolen, Michelle Petri, et al.
The Journal of Biological Chemistry|August 12, 2023
Quantitative proteomics and phosphoproteomics of PP2A-PPP2R5D variants reveal deregulation of RPS6 phosphorylation via converging signaling cascadesKali A Smolen, Cinta M Papke, Mark R Swingle, et al.
Scandinavian Journal of Rheumatology|May 30, 2020
Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritisP Emery, C-H Suh, M E Weinblatt, et al.
Rheumatology (Oxford, England)|May 19, 2012
Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trialEdward C Keystone, Bernard Combe, Josef Smolen, et al.
Arthritis Research & Therapy|May 19, 2005
The active metabolite of leflunomide, A77 1726, interferes with dendritic cell functionBernhard M Kirsch, Maximilian Zeyda, Karl Stuhlmeier, et al.
Annals of the Rheumatic Diseases|March 14, 2002
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)D E Furst, E C Keystone, F C Breedveld, et al.
Pageof 147

Showing results (1001-1010 of 1,467) with videos related to

Sort By:
Pageof 147
Arthritis and Rheumatism|July 13, 2004
Endothelial precursor cells in the synovial tissue of patients with rheumatoid arthritis and osteoarthritisBeate Rüger, Alexander Giurea, Axel H Wanivenhaus, et al.
Nature Reviews. Rheumatology|November 11, 2016
Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendationsLaure Gossec, Laura C Coates, Maarten de Wit, et al.
Antimicrobial Agents and Chemotherapy|September 29, 2020
Structural Insights into Inhibition of the Acinetobacter-Derived Cephalosporinase ADC-7 by Ceftazidime and Its Boronic Acid Transition State AnalogBrandy N Curtis, Kali A Smolen, Sara J Barlow, et al.
Annals of the Rheumatic Diseases|October 28, 2021
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated databasePeter C Taylor, Tsutomu Takeuchi, Gerd R Burmester, et al.
RMD Open|August 21, 2023
Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysisEric Morand, Josef S Smolen, Michelle Petri, et al.
The Journal of Biological Chemistry|August 12, 2023
Quantitative proteomics and phosphoproteomics of PP2A-PPP2R5D variants reveal deregulation of RPS6 phosphorylation via converging signaling cascadesKali A Smolen, Cinta M Papke, Mark R Swingle, et al.
Scandinavian Journal of Rheumatology|May 30, 2020
Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritisP Emery, C-H Suh, M E Weinblatt, et al.
Rheumatology (Oxford, England)|May 19, 2012
Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trialEdward C Keystone, Bernard Combe, Josef Smolen, et al.
Arthritis Research & Therapy|May 19, 2005
The active metabolite of leflunomide, A77 1726, interferes with dendritic cell functionBernhard M Kirsch, Maximilian Zeyda, Karl Stuhlmeier, et al.
Annals of the Rheumatic Diseases|March 14, 2002
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)D E Furst, E C Keystone, F C Breedveld, et al.
Pageof 147